Skip to main content
main-content

Neonatal diabetes

News

10-28-2020 | Canagliflozin | News

Canagliflozin linked to reduced anemia risk in people with type 2 diabetes, CKD

Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.

10-26-2020 | Early onset | News

Researchers propose early-onset type 2 diabetes phenotype

Younger age at onset of type 2 diabetes is associated with a significantly increased risk for cardiovascular death, as well as an increased likelihood of having offspring who will also develop diabetes, Framingham Heart Study data show.

10-23-2020 | Nephropathy | News

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

Read more

Opinion

10-14-2020 | Type 2 diabetes | Editorial | Article

Tirzepatide: A new challenger for type 2 diabetes management?

What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

03-03-2020 | Guidelines | Editorial | Article

Standards of Medical Care in Diabetes: A 2020 Update from the American Diabetes Association

Sanjay Kalra, Diabetologist and Editorial Board member, outlines what's new in the American Diabetes Association’s 2020 Standards of Care update. 

In depth

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.

10-16-2019 | Continuous glucose monitoring | Feature | Article

CGM time in range: A higher standard for an engaged few?

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Original research

02-16-2017 | Gestational diabetes | OriginalPaper | Article

Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012

This study assesses the risk of adverse perinatal outcomes in gestational diabetes mellitus in a large national cohort. gestational diabetes mellitus is associated with a moderately increased risk of adverse perinatal outcomes, which is higher in insulin-treated gestational diabetes mellitus than in non-insulin-treated gestational diabetes mellitus for most outcomes.

Billionnet C et al. Diabetologia 2017;60:636–644. doi:10.1007/s00125-017-4206-6

Related news story: Nationwide study confirms risks of gestational diabetes

Journal articles and book chapters

07-17-2020 | COVID-19 | Review | Article

Diabetes and novel coronavirus infection: Implications for treatment

The authors explore the potential biological mechanisms by which SARS-CoV-2 may interact with disease processes implicated in diabetes in this short review.

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

12-07-2018 | Pathogenesis | Review | Article

Melatonin in type 2 diabetes mellitus and obesity

Katamitri A, Jockers R. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0130-1

In practice

06-01-2017 | Type 2 diabetes | Review | Article

Practical recommendations for transitioning patients with type 2 diabetes from hospital to home

Donihi AC. Curr Diab Rep 2017; 17: 52. doi: 10.1007/s11892-017-0876-1

04-04-2017 | Screening | Article

Understanding type 2 diabetes mellitus screening practices among primary care physicians: A qualitative chart-stimulated recall study

Hafez D et al. BMC Fam Pract 2017; 18: 50. doi: 10.1186/s12875-017-0623-3

02-16-2017 | Type 2 diabetes | In practice | Article

The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy

Meece J. Adv Ther 2017; 34: 638–657. doi: 10.1007/s12325-017-0491-1

Case reports

Image Credits